The life expectancy of patients with high-grade glioma (HGG) has not improved in decades.
One of the crucial tools to enable future improvement is advanced models that faithfully …

High-grade gliomas are the most common and aggressive malignant primary brain tumors.
Current therapeutic schemes include a combination of surgical resection, radiotherapy and …

Glioblastoma (GBM) is the most malignant and highly aggressive brain tumor. In this study,
four types of typical GBM cell lines (LN229, SNB19, U87, U251) were cultured in a …

Background A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …

Immunotherapy efficacy as monotherapy is negligible for glioblastoma (GBM). We
hypothesized that combining therapeutic vaccination using a plasmid encoding an epitope …

Background Glioblastoma (GBM) has been extensively researched over the last few
decades, yet despite aggressive multimodal treatment, recurrence is inevitable and second …

Graphene‐based 2D nanomaterials possess unique physicochemical characteristics which
can be utilized in various biomedical applications, including the transport and presentation …

The discovery of the isocitrate dehydrogenase (IDH) mutation in glioma led to a paradigm
shift on how we see glioma biology. Difficulties in cultivating IDH mutant glioma stem cells …

Glioblastoma (GBM) is the most aggressive brain tumor, and the prognosis remains poor
with current available treatments. PDIA1 is considered a promising therapeutic target in …

Glioblastoma (GBM) remains a cancer of high unmet clinical need. Current standard of care
for GBM, consisting of maximal surgical resection, followed by ionisation radiation (IR) plus …